Population Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis

Author(s): Petra Jauslin, Pooja Kulkarni, Russell Wada, Suresh Vatakuti, Azher Hussain, Larissa Wenning, Thomas Kerbusch
Year:

Learn More LinkedIn Twitter Facebook Email